References
- Terui T. New possibility of the treatment of palmoplantar pustulosis. Nihon Hifuka Gakkai Zasshi. 2010;120:290–1
- Approval Information for PMDA (Pharmceuticals and Medical Devices Agency) in Japan. Available from http://www.info.pmda.go.jp/
- Barker JN, Ashton RE, Marks R, et al. Topical maxacalcitol for the treatment of prosiasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. Br J Dermatol. 1999;141:274–8
- Okubo Y. How does palmoplantar pustulosis reduce a patient’s QOL? J Visual Dermatol. 2012;11:1032–5
- Ozawa M, Terui T, Tagami H. Localization of IL-8 and complement components in lesional skin of psoriasis vulgaris and pustulosis palmaris et plantaris. Dermatology. 2005;211:249–55
- Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest. 2004;113:1664–75
- Teunissen MB, Koomen CW, de Waal Malefyt R, et al. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol. 1998;111:645–9
- Komine M, Watabe Y, Shimaoka S, et al. The action of a novel vitamin D3 analogue, OCT, on immunomodulatory function of keratinocytes and lymphocytes. Arch Dermatol Res. 1999;291:500–6
- Zhang JZ, Maruyama K, Ono I, et al. Regulatory effects of 1,25-dihydroxyvitamin D3 and a novel vitamin D3 analogue MC903 on secretion of interleukin-1 alpha (IL-1 alpha) and IL-8 by normal human keratinocytes and a human squamous cell carcinoma cell line (HSC-1). J Dermatol Sci. 1994;7:24–31
- van Hamburg JP, Asmawidjaja PS, Davelaar N, et al. TNF blockade requires 1,25(OH)2D3 to control human Th17-mediated synovial inflammation. Ann Rheum Dis. 2012;71:606–12
- Peric M, Koglin S, Dombrowski Y, et al. Vitamin D analogs differentially control antimicrobial peptide/“alarmin” expression in psoriasis. PLoS One. 2009;22;4:e6340